Caption Management’s Neurocrine Biosciences NBIX Stock Holding History

Caption Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30,000	Closed	-$3.95M	–	1916
2026 Q1	$3.95M	Buy	+30,000	New	+$3.98M	0.02%	602
2025 Q4	–	Sell	-53,000	Closed	-$7.44M	–	1917
2025 Q3	$7.44M	Buy	53,000 +13,000	+33%	+$1.76M	0.06%	362
2025 Q2	$5.03M	Sell	40,000 -110,300	-73%	-$12.6M	0.06%	408
2025 Q1	$16.6M	Buy	+150,300	New	+$19M	0.16%	115
2024 Q2	–	Sell	-25,000	Closed	-$3.45M	–	1391
2024 Q1	$3.45M	Sell	25,000 -29,900	-54%	-$4.08M	0.05%	389
2023 Q4	$7.23M	Buy	54,900 +22,400	+69%	+$2.58M	0.1%	249
2023 Q3	$3.66M	Buy	32,500 +2,500	+8%	+$263K	0.06%	408
2023 Q2	$2.83M	Hold	30,000	–	–	0.05%	417
2023 Q1	$3.04M	Buy	30,000 +10,000	+50%	+$1.04M	0.06%	343
2022 Q4	$2.39M	Buy	+20,000	New	+$2.34M	0.04%	512
2022 Q3	–	Sell	-55,000	Closed	-$5.36M	–	1733
2022 Q2	$5.36M	Sell	55,000 -85,000	-61%	-$7.85M	0.07%	327
2022 Q1	$13.1M	Buy	140,000 +80,000	+133%	+$6.78M	0.16%	153
2021 Q4	$5.11M	Sell	60,000 -30,000	-33%	-$2.76M	0.06%	451
2021 Q3	$8.63M	Buy	90,000 +30,000	+50%	+$2.83M	0.1%	268
2021 Q2	$5.84M	Buy	+60,000	New	+$5.75M	0.08%	336
2021 Q1	–	Sell	-80,000	Closed	-$7.67M	–	1277
2020 Q4	$7.67M	Buy	80,000 +11,000	+16%	+$1.06M	0.17%	157
2020 Q3	$6.64M	Buy	69,000 +39,000	+130%	+$4.51M	0.16%	159
2020 Q2	$3.66M	Hold	30,000	–	–	0.12%	227
2020 Q1	$2.6M	Buy	30,000 +5,000	+20%	+$489K	0.15%	192
2019 Q4	$2.69M	Buy	+25,000	New	+$2.62M	0.09%	306
2019 Q3	–	Sell	-30,000	Closed	-$2.53M	–	831
2019 Q2	$2.53M	Sell	30,000 -55,000	-65%	-$4.52M	0.13%	213
2019 Q1	$7.49M	Buy	+85,000	New	+$7.1M	0.41%	64

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Caption Management's NBIX Position: Q2 2026 in Review

Caption Management increased its Neurocrine Biosciences (NBIX) stake by 231% in Q2 2026, buying an estimated $3.06M and bringing the position to 29,500 shares worth $4.97M. The position accounts for 0.02% of the portfolio, ranked #583.

Caption Management first reported a position in NBIX in Q1 2019 and has held it in 18 quarters since. The position peaked at $14.5M in Q1 2025. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Caption Management held 29,500 shares of Neurocrine Biosciences worth $4.97M as of Q2 2026.
Caption Management bought 20,600 Neurocrine Biosciences shares in Q2 2026, an estimated $3.06M.
Neurocrine Biosciences made up 0.02% of Caption Management's portfolio in Q2 2026, its #583 holding.
Caption Management first reported a position in Neurocrine Biosciences in Q1 2019 and has held it in 18 quarters since.
Caption Management's Neurocrine Biosciences position peaked at $14.5M in Q1 2025.
777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.